Phico Therapeutics gains £13.1m grant to advance antibacterial therapy
SASPject PT3.9 is designed for the treatment of hospital infections caused by Pseudomonas aeruginosa
Read More
Tag: antibacterial resistance
- European life sciences coalition launched to boost investment ecosystem
- 99mtc‑maraciclatide granted fast track status for ILD imaging
- Bioxytran reports rapid viral clearance in phase 2 trial
- Thx Pharma and Biocodex sign rare disease licensing deal
- AstraZeneca bladder cancer therapy wins NICE backing
